Torin 1

Catalog No.S2827

Molecular Weight(MW): 607.62

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.

Cited by 16 Publications

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Autophagy, 2019, 1-13

PubMed: 30957628 ( click the link to review the publication )

Cell Rep, 2019, 27(7):2075-2091.e5

PubMed: 31091447 ( click the link to review the publication )

Lab Invest, 2019, 99(5):648-658

PubMed: 30679758 ( click the link to review the publication )

Biochem Pharmacol, 2019, 162:191-201

PubMed: 30471247 ( click the link to review the publication )

Lung Cancer, 2018, 120:34-45

PubMed: 29748013 ( click the link to review the publication )

Exp Cell Res, 2018, 363(1):84-94

PubMed: 29289595 ( click the link to review the publication )

J Cell Physiol, 2016, 10.1002/jcp.25456

PubMed: 27301841 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 25846574 ( click the link to review the publication )

J Biol Chem, 2015, 10.1074/jbc.M114.621706

PubMed: 25878248 ( click the link to review the publication )

J Biol Chem, 2015, 290(9):5592-605

PubMed: ( click the link to review the publication )

Am J Pathol, 2014, 184(1):214-29

PubMed: 24215913 ( click the link to review the publication )

J Biol Chem, 2014, 289(43):29739-49

PubMed: 25164809 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(24):4474-84

PubMed: 25288641 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.05.047

PubMed: 24858682 ( click the link to review the publication )

PLoS One, 2013, 8(11):e80070

PubMed: 24244612 ( click the link to review the publication )

5 Customer Reviews

Huh-7.5 cells were treated with increasing concentration of Torin 1, a known autophagy inducer, and the autophagy response was assessed by measuring LC3II and p62 levels.

Am J Pathol 2014 184(1), 214-29. Torin 1 purchased from Selleck.
Flag-tagged SENP3 was immunoprecipitated from HeLa cells and used for in vitro phosphorylation assay with [32P]ATP with either the mock-treated or Torin1-treated mTOR/Raptor/MLST8 complex. (Upper) The samples then were subjected to SDS-PAGE, followed by autoradiography. mTOR autophosphorylation is indicated by an asterisk. (Lower) Immunopurified SENP3 was monitored by Western blotting with anti-Flag antibody.

Mol Cell Biol 2014 34(24), 4474-84. Torin 1 purchased from Selleck.
Representative Western blots showing LC3 in PP242 (PP) or Torin1 (Tor) treated HepG2 cells. HepG2 cells were treated with 10 uM PP242 or 0.1 uM Torin1 for 24 h.

Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.05.047. Torin 1 purchased from Selleck.
Bone marrow derived macrophages were pre-treated with 10nM Torin 1 for 1h prior to LPS treatment (100 ng/ml). TNF-a production was analyzed 24h later.

Lim Hsiu Kim, Lina from National University of Singapore. Torin 1 purchased from Selleck.
Exp Cell Res, 2018, 363(1):84-94. Torin 1 purchased from Selleck.

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.

Targets

mTORC1 ^[1] (Cell-free assay)	mTOR ^[2] (Cell-free assay)	DNA-PK ^[2] (Cell-free assay)	mTORC2 ^[1] (Cell-free assay)	p110γ ^[2] (Cell-free assay)	View More
2 nM	4.32 nM	6.34 nM	10 nM	171 nM	View More

In vitro

Torin1 inhibits phosphorylation of mTORC1 and mTORC2 substrates in cells at concentrations of 2 and 10 nM, respectively. Moreover, Torin1 exhibits 1000-fold selectivity for mTOR over PI3K (EC50 = 1800 nM) and exhibits 100-fold binding selectivity relative to 450 other protein kinases. ^[1] ^[2] Torin1 causes cell cycle arrest through a rapamycin-resistant mechanism that is also independent of mTORC2. Torin1 disrupts mTORC1-dependent phenotypes more completely than rapamycin. Rapamycin-resistant functions of mTORC1 are required for cap-dependent translation. ^[1] In a recent study, it is reported Torin1 increases neurotensin secretion and gene expression through activation of the MEK/ERK/c-Jun pathway in the human endocrine cell line BON. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
ETK-1	NYPyV3NsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2XadGlEPTB;MD6wNFA{ODZizszN	MknXV2FPT0WU
OCUB-M	NEnPRoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYjKWJM1UUN3ME2wMlAxOTl2IN88US=>	MnrkV2FPT0WU
DOHH-2	NGHsV5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTQXHBDUUN3ME2wMlAxOjJ3IN88US=>	MV7TRW5ITVJ?
NOS-1	NEXsNI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTBwMECyOFIh\|ryP	MkfWV2FPT0WU
L-363	NXfoWYdyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEH5XFhKSzVyPUCuNFAzQDRizszN	MUTTRW5ITVJ?
RL95-2	NIfYeXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2D1d2lEPTB;MD6wNFMzKM7:TR?=	MX3TRW5ITVJ?
BL-70	M{DLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkT1TWM2OD1yLkCwN\|M4KM7:TR?=	NY\HRm4xW0GQR1XS
TGBC1TKB	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFPUXWZKSzVyPUCuNFA{PzlizszN	MlXQV2FPT0WU
697	NVq0XYhMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXwOIE4UUN3ME2wMlAxPjN2IN88US=>	M4K1TnNCVkeHUh?=
RPMI-8226	Mn[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTBwMEC2OVEh\|ryP	NVrhU3lGW0GQR1XS
BL-41	NHviT3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTBwMEC2PVYh\|ryP	NYnFPWN[W0GQR1XS
MRK-nu-1	M{nXb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoruTWM2OD1yLkCwO\|A4KM7:TR?=	NXr1ZWt4W0GQR1XS
EW-1	NFPWSmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFvtdGxKSzVyPUCuNFA4PDlizszN	NWHD[GJkW0GQR1XS
EVSA-T	NYr0VWt3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlvRTWM2OD1yLkCwPFkzKM7:TR?=	MnPWV2FPT0WU
HUTU-80	M4D6eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHkR2JzUUN3ME2wMlAxQTJ7IN88US=>	MmTvV2FPT0WU
VA-ES-BJ	NHrDOYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mmm4TWM2OD1yLkCwPVg1KM7:TR?=	M{frVHNCVkeHUh?=
GCIY	NX7SO49mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4e1fGlEPTB;MD6wNVAxPyEQvF2=	M1jBXnNCVkeHUh?=
ES6	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXtTWM2OD1yLkCxNFg{KM7:TR?=	NEH5T3dUSU6JRWK=
NALM-6	NH\LVHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGXjTHZKSzVyPUCuNFEyODJizszN	M3zGdnNCVkeHUh?=
LB996-RCC	NYWxdIk4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LB[WlEPTB;MD6wNVE{PyEQvF2=	MlK2V2FPT0WU
EW-16	M1nqWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXrTWM2OD1yLkCxNVkzKM7:TR?=	NVXDe2FTW0GQR1XS
KALS-1	MlXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTBwMEGxPVgh\|ryP	NIf6d4ZUSU6JRWK=
OPM-2	M3zxVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnyzTWM2OD1yLkCxNlkh\|ryP	MVjTRW5ITVJ?
KU812	M4PadWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWTnOW1UUUN3ME2wMlAyOjl4IN88US=>	MoDKV2FPT0WU
A4-Fuk	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTBwMEGzNVkh\|ryP	NVzj[XFYW0GQR1XS
KGN	M1S3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3ixXGlEPTB;MD6wNVM2QSEQvF2=	MVfTRW5ITVJ?
KS-1	NIj1W5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknSTWM2OD1yLkCxN\|kzKM7:TR?=	MmXaV2FPT0WU
no-11	NHi4VoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFG1VGVKSzVyPUCuNFE{QTVizszN	NYjrT\|dYW0GQR1XS
PSN1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTBwMEG0NFkh\|ryP	NWqzeoZNW0GQR1XS
SK-LMS-1	NXPaT4lyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTBwMEG0NVMh\|ryP	MnnFV2FPT0WU
LS-411N	M{j4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPnUXZKSzVyPUCuNFE1OzlizszN	MU\TRW5ITVJ?
HT-144	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV:1emU2UUN3ME2wMlAyPDVzIN88US=>	NHvjUYRUSU6JRWK=
ACN	M{LxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4SwUmlEPTB;MD6wNVUh\|ryP	NVK2S\|AyW0GQR1XS
RKO	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX;JR\|UxRTBwMEG1N\|Mh\|ryP	MV3TRW5ITVJ?
CMK	MoHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkH0TWM2OD1yLkCxOVQ{KM7:TR?=	M4rIdHNCVkeHUh?=
GB-1	NF:2VlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2fF[mlEPTB;MD6wNVU2OyEQvF2=	NEfmVWNUSU6JRWK=
KE-37	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\BTWM2OD1yLkCxOVc{KM7:TR?=	M3jmV3NCVkeHUh?=
no-10	MkjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoHqTWM2OD1yLkCxOVg1KM7:TR?=	NVLaU\|NVW0GQR1XS
MOLT-16	NVHBOpp2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTBwMEG2NlIh\|ryP	NXv2dFVZW0GQR1XS
HEL	NGPqUJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{CySWlEPTB;MD6wNVY1KM7:TR?=	NEnWU4pUSU6JRWK=
NCI-H1355	M4\ZVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHmwfFRKSzVyPUCuNFE3PDZizszN	MYDTRW5ITVJ?
IST-MEL1	NETzUIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TXUGlEPTB;MD6wNVc4PCEQvF2=	NVn5b4gxW0GQR1XS
MHH-PREB-1	MkfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEjwcoxKSzVyPUCuNFE5OThizszN	MUDTRW5ITVJ?
ES8	M{Ll[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTBwMEG4OFQh\|ryP	NIq1SoRUSU6JRWK=
LC-2-ad	NX;qTXBPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrYTWM2OD1yLkCyNVM4KM7:TR?=	MU\TRW5ITVJ?
LAMA-84	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\3OWlEPTB;MD6wNlE3PyEQvF2=	MW\TRW5ITVJ?
BV-173	NFHrU4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfRTG1KSzVyPUCuNFIzODNizszN	MnjrV2FPT0WU
SW872	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIPEPY5KSzVyPUCuNFIzPDdizszN	MlrLV2FPT0WU
SK-UT-1	NWK1eZpLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vwWWlEPTB;MD6wNlI3OSEQvF2=	MUfTRW5ITVJ?
OS-RC-2	Mn\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTBwMEKzNlMh\|ryP	MWDTRW5ITVJ?
NCI-H747	Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1yyW2lEPTB;MD6wNlM{KM7:TR?=	NVr4[\|lnW0GQR1XS
MZ2-MEL	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX;JR\|UxRTBwMEKzN\|ch\|ryP	NY[wUnJwW0GQR1XS
TE-11	MnfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4m3RmlEPTB;MD6wNlM4OiEQvF2=	MULTRW5ITVJ?
KURAMOCHI	M1n0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnXjTWM2OD1yLkCyOFE1KM7:TR?=	NHrIbYFUSU6JRWK=
HD-MY-Z	NVj2U\|BnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTBwMEK0NlYh\|ryP	MkS4V2FPT0WU
GI-1	MknqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;DfoFtUUN3ME2wMlAzPDZ7IN88US=>	NUfRSHRZW0GQR1XS
LB1047-RCC	M1zLU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTBwMEK0PFgh\|ryP	M3rCWnNCVkeHUh?=
TE-12	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTBwMEK1OUDPxE1?	M2nBU3NCVkeHUh?=
MZ7-mel	MoTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPjdlFPUUN3ME2wMlAzPjB7IN88US=>	M2T1[3NCVkeHUh?=
MMAC-SF	MoXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTBwMEK2N\|Mh\|ryP	MoWzV2FPT0WU
A101D	M4Xae2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHyNGk4UUN3ME2wMlAzPjVizszN	Mne4V2FPT0WU
GR-ST	NUTSZYpzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1u1bWlEPTB;MD6wNlY2PSEQvF2=	NVTMbWk5W0GQR1XS
MC116	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnRc2NpUUN3ME2wMlAzPjhizszN	M2j0eHNCVkeHUh?=
Ramos-2G6-4C10	MlfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjYRVBnUUN3ME2wMlAzPzVizszN	MmDoV2FPT0WU
ATN-1	M{DpdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXkU3VKSzVyPUCuNFI4QDlizszN	MkDTV2FPT0WU
MFH-ino	NYm5V2hyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXw[VFpUUN3ME2wMlAzQDF{IN88US=>	MnXrV2FPT0WU
DEL	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3vFS2lEPTB;MD6wNlgyPSEQvF2=	M{jJ[XNCVkeHUh?=
OCI-AML2	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\KTWM2OD1yLkCyPFcyKM7:TR?=	M{TYTXNCVkeHUh?=
LXF-289	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTBwMEK4O\|Ih\|ryP	MoLQV2FPT0WU
IA-LM	M1K1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUjkcY9rUUN3ME2wMlAzQTF5IN88US=>	NFKzUlVUSU6JRWK=
EoL-1-cell	M2nHc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTBwMEK5PVYh\|ryP	MkfLV2FPT0WU
OVCAR-4	NUHwNllsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjLWGxLUUN3ME2wMlA{ODl2IN88US=>	M4jtTnNCVkeHUh?=
ES1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXDVWtKSzVyPUCuNFMxQTdizszN	NUPPdm16W0GQR1XS
CESS	NW\ISJhjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPscWFKSzVyPUCuNFMxQTlizszN	MVfTRW5ITVJ?
GAK	M322[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXWbGRNUUN3ME2wMlA{OTh4IN88US=>	M2LJdXNCVkeHUh?=
NTERA-S-cl-D1	NUi2XJBjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXLrd2dRUUN3ME2wMlA{OjJ4IN88US=>	MkD2V2FPT0WU
TE-10	NFLaXVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLJdGNKSzVyPUCuNFM{OTFizszN	NHfQeY1USU6JRWK=
CCRF-CEM	NHi5codIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnhbpNKSzVyPUCuNFM{PzFizszN	NFnubmlUSU6JRWK=
NMC-G1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfVblJKSzVyPUCuNFM1PDhizszN	NXK5WY86W0GQR1XS
HOP-62	NUPVcWFxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmHWTWM2OD1yLkCzOVU3KM7:TR?=	NWXI[2ViW0GQR1XS
SH-4	MnvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTBwMEO1PFIh\|ryP	NGmzcVFUSU6JRWK=
NCI-H1648	M2nqTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmqxTWM2OD1yLkCzOlIzKM7:TR?=	MYfTRW5ITVJ?
EB-3	M4LBR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2H4W2lEPTB;MD6wN\|Y1OyEQvF2=	MkC2V2FPT0WU
BB65-RCC	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHw[4d[UUN3ME2wMlA{PjlzIN88US=>	MnHEV2FPT0WU
BE-13	M37xXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWTrdIszUUN3ME2wMlA{PzV7IN88US=>	M{TlNHNCVkeHUh?=
CP67-MEL	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HyNmlEPTB;MD6wN\|c2QSEQvF2=	MXXTRW5ITVJ?
SW954	NFPXWIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3O1WWlEPTB;MD6wN\|c6KM7:TR?=	MlP3V2FPT0WU
TE-5	MkjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\ae4VKSzVyPUCuNFM5PTRizszN	MlWyV2FPT0WU
HCE-4	MmP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7ybGdjUUN3ME2wMlA{QDV3IN88US=>	MkjwV2FPT0WU
LC-1F	MkG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3q0RWlEPTB;MD6wN\|k5QSEQvF2=	M4e2O3NCVkeHUh?=
TK10	M3TocWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUDJR\|UxRTBwMESwNVkh\|ryP	MVTTRW5ITVJ?
SJSA-1	M{XJSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1jFTmlEPTB;MD6wOFE5QCEQvF2=	MX\TRW5ITVJ?
Daudi	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnLTWM2OD1yLkC0NlI2KM7:TR?=	NX35N4htW0GQR1XS
SW982	NYTC[mp5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX63XndYUUN3ME2wMlA1OjR4IN88US=>	MnLxV2FPT0WU
SF126	MlnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTBwMESzOlEh\|ryP	MXrTRW5ITVJ?
TE-15	M2nZWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2LFTGlEPTB;MD6wOFQ{PSEQvF2=	NUfaPIFHW0GQR1XS
COLO-684	M37HcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTBwMES1OlEh\|ryP	MUDTRW5ITVJ?
8-MG-BA	NEXuempIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\PeItKSzVyPUCuNFQ3OjlizszN	MoXFV2FPT0WU
NB13	Mlr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkTBTWM2OD1yLkC0O\|c3KM7:TR?=	NH3RUGlUSU6JRWK=
HCC1599	M2PmOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYj0[JBLUUN3ME2wMlA1QDd7IN88US=>	MknRV2FPT0WU
SK-PN-DW	M{K1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUPkb3BDUUN3ME2wMlA1QTR7IN88US=>	M3PyZXNCVkeHUh?=
ALL-PO	M4Lk[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTBwMES5OVYh\|ryP	MU\TRW5ITVJ?
NB6	MnTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHrpdlhKSzVyPUCuNFUzPzFizszN	M1TrPHNCVkeHUh?=
IST-SL2	NIrUSoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mkf5TWM2OD1yLkC1N\|YzKM7:TR?=	NFfnfnJUSU6JRWK=
BB30-HNC	NYexUWhDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHTR[2hKSzVyPUCuNFU4OyEQvF2=	MmfJV2FPT0WU
SW962	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2XyT2lEPTB;MD6wOVc3OyEQvF2=	MlTyV2FPT0WU
TGBC24TKB	MmXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4C0UGlEPTB;MD6wOVc6QSEQvF2=	NFyxTJJUSU6JRWK=
KINGS-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTBwMEW4NFMh\|ryP	M4XaSXNCVkeHUh?=
HC-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2PqeGlEPTB;MD6wOVgzPyEQvF2=	NIXOW2RUSU6JRWK=
RS4-11	NUXVc3JDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTBwMEW5N\|gh\|ryP	MofyV2FPT0WU
LS-123	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV\JR\|UxRTBwMEW5OFIh\|ryP	NX7UVml3W0GQR1XS
A3-KAW	NV\HcG1sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTBwME[yNlUh\|ryP	Mn\mV2FPT0WU
SNB75	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXM[4tKSzVyPUCuNFY{PDFizszN	M3jtd3NCVkeHUh?=
SR	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mny2TWM2OD1yLkC2N\|c1KM7:TR?=	NWPYeod5W0GQR1XS
LOUCY	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfPOYtXUUN3ME2wMlA3Ozl2IN88US=>	NGD2emxUSU6JRWK=
K5	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjSRWRoUUN3ME2wMlA3PDB\|IN88US=>	NViybZFJW0GQR1XS
Becker	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTBwME[0NkDPxE1?	MkfVV2FPT0WU
CTV-1	MlHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofpTWM2OD1yLkC2OVQ5KM7:TR?=	MYrTRW5ITVJ?
KLE	M3XWRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTBwME[1PFQh\|ryP	NWK2PFFJW0GQR1XS
MZ1-PC	MnXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HzOmlEPTB;MD6wOlU6QCEQvF2=	MYDTRW5ITVJ?
MOLT-4	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoTGTWM2OD1yLkC2OlA2KM7:TR?=	NVKxdIJQW0GQR1XS
MLMA	NFXVNZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTBwME[3PEDPxE1?	NYfSb2JjW0GQR1XS
A388	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\D[Zg{UUN3ME2wMlA3QDl\|IN88US=>	MWLTRW5ITVJ?
MV-4-11	Mly1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2TmNmlEPTB;MD6wOlk6PSEQvF2=	MnXVV2FPT0WU
DSH1	NIL5XYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEmwNYdKSzVyPUCuNFcyPzNizszN	M4S5OXNCVkeHUh?=
MONO-MAC-6	M{OzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTBwMEeyNVIh\|ryP	M{TX[nNCVkeHUh?=
ARH-77	M4HVPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUnWVpljUUN3ME2wMlA4Ojd6IN88US=>	NWTQPFV1W0GQR1XS
LB771-HNC	M{i2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUC1SWt6UUN3ME2wMlA4PTR7IN88US=>	M{jhcXNCVkeHUh?=
PF-382	NW\wToR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\qSWlEPTB;MD6wO\|U3QSEQvF2=	NH7CRXRUSU6JRWK=
KM12	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\vTWM2OD1yLkC3OlQh\|ryP	NFf0eXNUSU6JRWK=
HAL-01	NVfLeXZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTBwMEe2OVgh\|ryP	M{L2Z3NCVkeHUh?=
RPMI-8402	NFi2dWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jXfWlEPTB;MD6wO\|c5QSEQvF2=	MoXsV2FPT0WU
OMC-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTBwMEe4NFQh\|ryP	MnXWV2FPT0WU
HT	MmDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;iPWZMUUN3ME2wMlA5KM7:TR?=	M1m4enNCVkeHUh?=
QIMR-WIL	NIXFOlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTBwMEiwOVUh\|ryP	MnnBV2FPT0WU
KNS-42	NVmwPIZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmjZTWM2OD1yLkC4NlA{KM7:TR?=	NUfhXY04W0GQR1XS
BC-3	M2DsWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M17rTmlEPTB;MD6wPFIxPCEQvF2=	MX7TRW5ITVJ?
ES4	M2jzXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGHreoVKSzVyPUCuNFgzQTZizszN	MoXXV2FPT0WU
NCI-H23	M1nHbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTBwMEi0OEDPxE1?	M2izU3NCVkeHUh?=
LB2518-MEL	NEnmXZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXtTWM2OD1yLkC4Olk3KM7:TR?=	NXTwXmh1W0GQR1XS
LC4-1	NUXHfHdKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUCxfnBkUUN3ME2wMlA5PzN6IN88US=>	NUXsXHhRW0GQR1XS
SIG-M5	M2PzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzlPWhKSzVyPUCuNFg6ODRizszN	NIrOZVdUSU6JRWK=
LP-1	M173cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFPT[2hKSzVyPUCuNFg6OzhizszN	NHqzcZBUSU6JRWK=
TE-8	Mne2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFPTSVdKSzVyPUCuNFkxOTZizszN	MY\TRW5ITVJ?
K-562	MlHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{LndWlEPTB;MD6wPVEzKM7:TR?=	NIq4colUSU6JRWK=
J-RT3-T3-5	MmPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInNWotKSzVyPUCuNFkyPTNizszN	NXzmSWluW0GQR1XS
DU-4475	NHnke41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTBwMEmxOlUh\|ryP	NIX0UGhUSU6JRWK=
RXF393	NYrESpJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTBwMEm0OlIh\|ryP	M1K2PXNCVkeHUh?=
NB5	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTBwMEm2NlUh\|ryP	MlLHV2FPT0WU
A704	M2e3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfiXWpKSzVyPUCuNFk4PDFizszN	M2D2VnNCVkeHUh?=
SF268	NFXmemhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml3oTWM2OD1yLkC5PFI2KM7:TR?=	M3;XOHNCVkeHUh?=
UACC-257	NFjaeJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoXWTWM2OD1yLkC5PFM{KM7:TR?=	NWTkTFFVW0GQR1XS
L-428	NWTRNoZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXyNmdKSzVyPUCuNVA{OiEQvF2=	NVTxeWMxW0GQR1XS
ST486	MkXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkjLTWM2OD1yLkGwOlA3KM7:TR?=	MmXyV2FPT0WU
SK-MM-2	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTBwMUC3NFkh\|ryP	NWL3fZdQW0GQR1XS
COR-L279	MonjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnHNTWM2OD1yLkGwPFMzKM7:TR?=	NXrINWxXW0GQR1XS
JiyoyeP-2003	NWPqcJFiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3y2cGlEPTB;MD6xNFg1OyEQvF2=	MnjHV2FPT0WU
GT3TKB	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M374[mlEPTB;MD6xNFkyQCEQvF2=	NFfSN4JUSU6JRWK=
HCE-T	NUnMUXQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE[wU\|BKSzVyPUCuNVA6PCEQvF2=	MnS3V2FPT0WU
SBC-1	M1rGXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2nhfGlEPTB;MD6xNVEyQSEQvF2=	NX;VN5NNW0GQR1XS
KNS-81-FD	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\Bb2RKSzVyPUCuNVEzPzNizszN	MXLTRW5ITVJ?
NCI-H2126	M{XNcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3q5e2lEPTB;MD6xNVM6PCEQvF2=	NFXuSVFUSU6JRWK=
EM-2	MknBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37CRWlEPTB;MD6xNVUzQSEQvF2=	NH\MS2lUSU6JRWK=
JAR	M4DqZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIXpTHFKSzVyPUCuNVE2QThizszN	MV3TRW5ITVJ?
NB17	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrmXVBLUUN3ME2wMlEyPjV{IN88US=>	MWXTRW5ITVJ?
LB647-SCLC	M3rGc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTBwMUG3NFUh\|ryP	M3HUd3NCVkeHUh?=
CAL-148	M3G5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3PIVGlEPTB;MD6xNVgh\|ryP	MlPkV2FPT0WU
K052	NX3vS2VJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknkTWM2OD1yLkGxPFUyKM7:TR?=	MWjTRW5ITVJ?
KARPAS-299	NWjtcVJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml\iTWM2OD1yLkGyNlM{KM7:TR?=	M4Xn[nNCVkeHUh?=
KARPAS-422	NG\jT5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHPRUoNKSzVyPUCuNVI1OzJizszN	MYrTRW5ITVJ?
LOXIMVI	MmLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIHVR3dKSzVyPUCuNVI2OTVizszN	NH2zO4lUSU6JRWK=
SCC-3	NYLBUo5FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTBwMUK4OVEh\|ryP	NHLZbmJUSU6JRWK=
LU-139	NUDmNXBVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HmXmlEPTB;MD6xNlk4PSEQvF2=	M2WzV3NCVkeHUh?=
COLO-320-HSR	NHnQXWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;FS\|JKSzVyPUCuNVMxQDZizszN	M2\VVXNCVkeHUh?=
ONS-76	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo[0TWM2OD1yLkGzNVMh\|ryP	NGfubGxUSU6JRWK=
U-266	M3zIOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXpTWM2OD1yLkGzNlQ2KM7:TR?=	Mn3EV2FPT0WU
HH	NX;McZBbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7oTWM2OD1yLkGzOVM2KM7:TR?=	M4XHTnNCVkeHUh?=
BB49-HNC	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\mVVl4UUN3ME2wMlE{PTh5IN88US=>	MlPiV2FPT0WU
NCI-SNU-5	Ml;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPIWHdKSzVyPUCuNVM2QTZizszN	NWDDd2gxW0GQR1XS
C2BBe1	MorSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\GcWlEPTB;MD6xN\|c1PiEQvF2=	MYXTRW5ITVJ?
ML-2	NV\UWWdMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkKwTWM2OD1yLkGzPVU{KM7:TR?=	NYj1XZZEW0GQR1XS
SCH	MnL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFPZOmpKSzVyPUCuNVM6PzRizszN	M4GzZnNCVkeHUh?=
NCI-H82	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{XpV2lEPTB;MD6xOFExPCEQvF2=	MX\TRW5ITVJ?
MDA-MB-134-VI	NVvGV2NqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\YdpR2UUN3ME2wMlE1OjV{IN88US=>	MYHTRW5ITVJ?
SK-N-DZ	NHX5W5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2nuWmlEPTB;MD6xOFcyQSEQvF2=	NVTuWJppW0GQR1XS
HL-60	MkHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLVTWM2OD1yLkG0PVIh\|ryP	NIjTfWFUSU6JRWK=
LB373-MEL-D	MkK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGLtTHdKSzVyPUCuNVU2OzlizszN	NXjwPIlWW0GQR1XS
LB831-BLC	MmjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlK5TWM2OD1yLkG2NFc3KM7:TR?=	NWjEUJNjW0GQR1XS
SK-NEP-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVz3SnlVUUN3ME2wMlE3OTBzIN88US=>	NH;oVWtUSU6JRWK=
IMR-5	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkDvTWM2OD1yLkG2OFg{KM7:TR?=	NVnifWppW0GQR1XS
Calu-6	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVO5SVNrUUN3ME2wMlE3PTN5IN88US=>	NGnscGdUSU6JRWK=
NCI-H1882	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVq5dY9sUUN3ME2wMlE3PzJ6IN88US=>	MlnVV2FPT0WU
NCI-H446	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2frbGlEPTB;MD6xOlg6OSEQvF2=	NHzh[FBUSU6JRWK=
GI-ME-N	NXfp[FMyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTBwMUiwNkDPxE1?	NWfIbmM1W0GQR1XS
MPP-89	NV\0T3F[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF[zO2hKSzVyPUCuNVgyOjFizszN	NEnzc2NUSU6JRWK=
CGTH-W-1	MlO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlPzTWM2OD1yLkG4OFM3KM7:TR?=	NVO3WlVUW0GQR1XS
MEG-01	M3\VSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mmi2TWM2OD1yLkG4OlI5KM7:TR?=	NHnYN5hUSU6JRWK=
NCI-H748	NX36T3JNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTBwMUi5NVEh\|ryP	NFLZeVZUSU6JRWK=
COLO-829	MnXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHLNUY1KSzVyPUCuNlA3PzNizszN	NYKyeVhIW0GQR1XS
GOTO	NVuyfIpvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTBwMkC3N{DPxE1?	MYfTRW5ITVJ?
EW-3	MmLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\h[G9KSzVyPUCuNlE4OThizszN	MnzpV2FPT0WU
KY821	NXjjZ4hnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXjPdoNFUUN3ME2wMlIzODR3IN88US=>	NWrmcnh2W0GQR1XS
CTB-1	NVn2NmRYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV3JR\|UxRTBwMkKyNlgh\|ryP	NXPVXY9jW0GQR1XS
TALL-1	NFX6OndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYLkNVRJUUN3ME2wMlIzQTJzIN88US=>	MYLTRW5ITVJ?
NCI-H209	NV:5TopQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTBwMkK5OlIh\|ryP	MnT1V2FPT0WU
IST-MES1	NUfVfHBWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEfCZpRKSzVyPUCuNlM2OSEQvF2=	NEW3[JFUSU6JRWK=
DMS-114	NYP4ZodZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3XvUWlEPTB;MD6yN\|k6OyEQvF2=	NYrnXpJuW0GQR1XS
SNU-C2B	NFfndYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTBwMkSzNVYh\|ryP	MUfTRW5ITVJ?
DG-75	Ml;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoPXTWM2OD1yLkK2NVk2KM7:TR?=	NUPPe2NnW0GQR1XS
D-336MG	Mn;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTBwMk[1OVch\|ryP	NIHoeo1USU6JRWK=
KMOE-2	M4jMd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUn5bolCUUN3ME2wMlI4PTN6IN88US=>	M4\HZ3NCVkeHUh?=
NB1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTBwMke5NlYh\|ryP	NH7F[mZUSU6JRWK=
RH-1	NV;GbFh3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\oTWM2OD1yLkK3PVg6KM7:TR?=	MWfTRW5ITVJ?
TE-1	M1H6Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfKTWM2OD1yLkK4OFc6KM7:TR?=	MWnTRW5ITVJ?
RPMI-6666	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfJSYNHUUN3ME2wMlI5QDRizszN	MnfsV2FPT0WU
TE-9	NInr[I5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDNW4MxUUN3ME2wMlI5QTh3IN88US=>	MULTRW5ITVJ?
BT-474	NWLqNHVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrMNY1KSzVyPUCuNlk{OzRizszN	NHHkeWFUSU6JRWK=
COLO-668	M3nxVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTBwMkm0Nlkh\|ryP	MmjKV2FPT0WU
NCI-H1581	NHrtT2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\NbYdKSzVyPUCuNlk3QDlizszN	NH\id41USU6JRWK=
MN-60	NVjhOZhRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LhVWlEPTB;MD6yPVkxPSEQvF2=	M4TQOnNCVkeHUh?=
L-540	Mo\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XGWWlEPTB;MD6zNFA5OSEQvF2=	MXHTRW5ITVJ?
MOLT-13	NF\Hb25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVzySoRJUUN3ME2wMlMxOTh\|IN88US=>	NHXJU45USU6JRWK=
NCI-SNU-16	M3HF[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTBwM{CyNFUh\|ryP	NYPjTIdZW0GQR1XS
NCI-H64	NETSVlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUWwXHA{UUN3ME2wMlMxOzNzIN88US=>	MWTTRW5ITVJ?
CP66-MEL	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLHTWM2OD1yLkOxOFE2KM7:TR?=	NG\0RYJUSU6JRWK=
NB69	NHHSS3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFjsWmNKSzVyPUCuN\|IyQDhizszN	MV\TRW5ITVJ?
NCI-H2196	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFywOGlKSzVyPUCuN\|MxOzZizszN	MVHTRW5ITVJ?
MHH-CALL-2	M1;KTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zkemlEPTB;MD6zN\|Q3QCEQvF2=	NXnvfpA{W0GQR1XS
HCC2157	MnTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTBwM{O5OVQh\|ryP	M1jhNXNCVkeHUh?=
LS-1034	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\oWGlEPTB;MD6zOlM5QCEQvF2=	MmmzV2FPT0WU
BOKU	M3\JVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn;mTWM2OD1yLkO3NVk6KM7:TR?=	MmnUV2FPT0WU
GDM-1	M{naSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;FOnpiUUN3ME2wMlM4OjN2IN88US=>	MWTTRW5ITVJ?
TGW	MnvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmTyTWM2OD1yLkO3OFU{KM7:TR?=	NGLTUWFUSU6JRWK=
SNU-C1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1i3TWlEPTB;MD6zPFIyPSEQvF2=	NXLaeXBXW0GQR1XS
LS-513	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTBwM{mwO\|Eh\|ryP	NInve25USU6JRWK=
NOMO-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIrpR2tKSzVyPUCuN\|k6PzFizszN	M2jFPXNCVkeHUh?=
MS-1	NVrnS\|h{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV3VWHZCUUN3ME2wMlQxOTd5IN88US=>	Mn74V2FPT0WU
EKVX	NXq5U\|hVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3OxbWlEPTB;MD60OFQ3OSEQvF2=	NHrnfllUSU6JRWK=
SK-MEL-2	Mo[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIjxcFhKSzVyPUCuOFY1KM7:TR?=	NVfyTlFjW0GQR1XS
HCC1187	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPMTWM2OD1yLkS2O\|Y5KM7:TR?=	MVPTRW5ITVJ?
HCC2218	NFnlT3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTBwNEeyNlch\|ryP	M1XufXNCVkeHUh?=
NCI-H187	MkK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTBwNEe4OEDPxE1?	M{X5dnNCVkeHUh?=
DB	NX:3RWJjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4TWcGlEPTB;MD61NFA2PSEQvF2=	MnXRV2FPT0WU
NCI-H69	Mn3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTBwNUCyOFch\|ryP	MlSyV2FPT0WU
NCI-H1694	M3\wSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4X5WmlEPTB;MD61NFY6PyEQvF2=	Ml3KV2FPT0WU
CA46	M{jVSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTBwNUC5NVch\|ryP	M4\idHNCVkeHUh?=
EHEB	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;GTWM2OD1yLkWxNVk{KM7:TR?=	MmXXV2FPT0WU
NCCIT	MnvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2DDW2lEPTB;MD61OFMzOSEQvF2=	MkTZV2FPT0WU
NCI-H720	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnzoTWM2OD1yLkW0PVYzKM7:TR?=	M4\IZnNCVkeHUh?=
LU-134-A	NV7OVJZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nOOGlEPTB;MD61OVI6PiEQvF2=	MkTzV2FPT0WU
MC-CAR	NFf2OJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTBwNUW0N\|Eh\|ryP	NYi5S4l4W0GQR1XS
NEC8	M2\jSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1LWXWlEPTB;MD61OlE4OiEQvF2=	MYfTRW5ITVJ?
NCI-H524	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXTeGJxUUN3ME2wMlU5PzR6IN88US=>	M3rhbXNCVkeHUh?=
NCI-H1963	NVrx[nM{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;Eb2lEPTB;MD62NlU5KM7:TR?=	M3nTNHNCVkeHUh?=
SU-DHL-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXESXFbUUN3ME2wMlY1PTJ4IN88US=>	M2[3d3NCVkeHUh?=
NCI-H1522	NIfF[HpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fpe2lEPTB;MD62OFg5OyEQvF2=	M37NfnNCVkeHUh?=
NCI-H1155	NIDSd2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX[3RoVJUUN3ME2wMlY2OzVizszN	M1fYd3NCVkeHUh?=
D-263MG	NX3rVFZNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLFTGJKSzVyPUCuOlYyODFizszN	NHjJfG1USU6JRWK=
TE-6	MmThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDFTFZKSzVyPUCuOlgyODRizszN	Ml;rV2FPT0WU
NCI-H1417	M1LhNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUjJR\|UxRTBwNkm3NVEh\|ryP	M{O4NnNCVkeHUh?=
NCI-H510A	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWPQRXFJUUN3ME2wMlc4OjN4IN88US=>	NEHmRYxUSU6JRWK=
KARPAS-45	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIDje3JKSzVyPUCuO\|gzOzVizszN	NHXMZnJUSU6JRWK=
IST-SL1	M3vLN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlG1TWM2OD1yLki1PFI2KM7:TR?=	NY\SdFNHW0GQR1XS
COLO-824	NGGwdYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPNdIJjUUN3ME2wMlg4QDN3IN88US=>	MWXTRW5ITVJ?
NCI-H526	MmLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTBwOUC5OVgh\|ryP	M33uSXNCVkeHUh?=
NCI-H719	MoXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnrBTWM2OD1yLkm2OlU4KM7:TR?=	MU\TRW5ITVJ?
SF539	M2\xVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXLWYFUUUN3ME2wMlk5Ozl4IN88US=>	MWPTRW5ITVJ?
NKM-1	NGfWPYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnTDTWM2OD1yLkm4OlY{KM7:TR?=	NVfUTppZW0GQR1XS
A253	MojDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jZXGlEPTB;MD65PFg5PSEQvF2=	NIrnd\|NUSU6JRWK=
TE-441-T	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{nnbGlEPTB;MT6wOFM2KM7:TR?=	MkK3V2FPT0WU
COR-L88	NELvbmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NET3dYlKSzVyPUGuNVE{PTRizszN	NVPqeYVEW0GQR1XS
CPC-N	NY\heJpXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHfxb5lKSzVyPUGuNVU5QDhizszN	M2rpRnNCVkeHUh?=
NCI-H2107	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3flTGlEPTB;MT6xO\|I3OSEQvF2=	MkjTV2FPT0WU
ECC4	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkW2TWM2OD1zLkG4Olk{KM7:TR?=	M2[3dXNCVkeHUh?=
NCI-H2141	MmrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1jVfGlEPTB;MT6xPVI6QSEQvF2=	MXrTRW5ITVJ?
NCI-H1770	MlSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV7JR\|UxRTFwM{K5Nlgh\|ryP	M1PmU3NCVkeHUh?=
NCI-SNU-1	Mk\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY\JR\|UxRTFwM{OwOEDPxE1?	NIS4OGtUSU6JRWK=
LU-165	M3zldWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{TmZ2lEPTB;MT60OVQ3PyEQvF2=	MYjTRW5ITVJ?
Raji	MkPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTFwNEeyOVkh\|ryP	MV;TRW5ITVJ?
EW-24	MorCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFrVcG5KSzVyPUGuOVQ3OTlizszN	NXTvR2JJW0GQR1XS
KP-N-RT-BM-1	Mo\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfhUWdDUUN3ME2xMlU3PTVzIN88US=>	NX;BbI0{W0GQR1XS
SK-MEL-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTFwNkS4O\|ch\|ryP	M1zrR3NCVkeHUh?=
SCLC-21H	NYHrNYEzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vSUGlEPTB;MT62OlY2OSEQvF2=	NHPpWZdUSU6JRWK=
SIMA	Ml;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jLeGlEPTB;MT62PFI{OyEQvF2=	NEjpXVlUSU6JRWK=
NCI-H1304	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWLJR\|UxRTFwN{C3OlUh\|ryP	NITh[\|ZUSU6JRWK=
REH	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\nVXBFUUN3ME2xMlcyODd6IN88US=>	NV;peIJsW0GQR1XS
KP-N-YS	M2fHemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDZTWM2OD1zLkmzOVUyKM7:TR?=	MU\TRW5ITVJ?
DMS-153	NWnyTVg5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{CyfGlEPTB;MT65O\|U6KM7:TR?=	M3roeHNCVkeHUh?=
NB10	M{jMfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTJwMkC4O\|gh\|ryP	Mn7rV2FPT0WU
NCI-H345	MlX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2q4cWlEPTB;Mj62NVkxPSEQvF2=	NVXxfVBKW0GQR1XS
SK-N-FI	NWDlWphHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTJwN{WzPFEh\|ryP	MWjTRW5ITVJ?
NCI-H1092	NI[wfZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4i5WGlEPTB;Mj65OVM6PCEQvF2=	MVTTRW5ITVJ?
KM-H2	NVrn[IF[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1TO[2lEPTB;Mz62OVM6PiEQvF2=	M2PWTnNCVkeHUh?=
KG-1	MoixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoXnTWM2OD1\|LkexOlg5KM7:TR?=	M1zqZXNCVkeHUh?=
D-283MED	M4DneWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnS3TWM2OD1\|Lke1PFch\|ryP	MmOzV2FPT0WU
LU-65	NEjW[HJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLO[JNKSzVyPUSuNVE1QDVizszN	MXPTRW5ITVJ?
MSTO-211H	NVHKdYI6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnyTWM2OD12LkG4PFk5KM7:TR?=	NUnsUWRCW0GQR1XS
NCI-H2081	M2n0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1W3TmlEPTB;ND6yPVE4PCEQvF2=	MXHTRW5ITVJ?
D-247MG	NYLEV4Y6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\6TWM2OD12LkSzNVkyKM7:TR?=	MkjLV2FPT0WU
P31-FUJ	M4LkT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1LQbWlEPTB;ND60OVAyQSEQvF2=	NXO5TVR1W0GQR1XS
DMS-79	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVzRe45{UUN3ME20Mlk{OTh\|IN88US=>	NHuxcXdUSU6JRWK=
KASUMI-1	Mk[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTRwOUe1NFkh\|ryP	NX\IXGlNW0GQR1XS
JVM-3	NFjybmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MorKTWM2OD13LkK1NFE1KM7:TR?=	NF\BWIFUSU6JRWK=
LAN-6	M3j3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4r5eGlEPTB;NT61NVc{PiEQvF2=	MVXTRW5ITVJ?
DJM-1	M1;wcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rUV2lEPTB;NT61OlAzQSEQvF2=	M1Hi[nNCVkeHUh?=
JVM-2	NGPkU2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTnepIxUUN3ME21MlY4ODl{IN88US=>	M2DKO3NCVkeHUh?=
U-87-MG	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTVwOEm5OlQh\|ryP	M4\EPHNCVkeHUh?=
SHP-77	MljoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1jqeWlEPTB;NT65OFkzQCEQvF2=	NHXjSFVUSU6JRWK=
RPMI-8866	NFjRdpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MorITWM2OD14LkK3NFE{KM7:TR?=	M3T2RnNCVkeHUh?=
ES7	NF;MXpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUfPNVJJUUN3ME22MlM6QTJ2IN88US=>	M37j[HNCVkeHUh?=
WSU-NHL	NYnPO2RxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHoTWM2OD14LkWxOlA6KM7:TR?=	NX3UfYQ2W0GQR1XS
CAS-1	MnXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTdwMEm3OFkh\|ryP	M{LwNXNCVkeHUh?=
MHH-NB-11	M3\CWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M165emlEPTB;OD6yN\|E2OiEQvF2=	Ml;vV2FPT0WU
ES5	NHLacnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zIW2lEPTB;OT61NlI5PiEQvF2=	MmDTV2FPT0WU
HDLM-2	NEnm[WlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnrUTWM2OD17Lkm1PVAzKM7:TR?=	NVHqUnliW0GQR1XS
NCI-H2171	NVj6OHo6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPw[VRCUUN3ME2xNE42QTJ5IN88US=>	MYnTRW5ITVJ?
LNCaP-Clone-FGC	NUXHPZl1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\sTWM2OD1zMT6zO\|E5KM7:TR?=	M{f4eHNCVkeHUh?=
NCI-H1395	M3;jWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFvlVldKSzVyPUGyMlI3QTlizszN	M{DoUnNCVkeHUh?=
NCI-H1436	NIXyfFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzVfJdKSzVyPUGzMlMyQTVizszN	Mn7iV2FPT0WU
RCC10RGB	M334dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLPT4ZOUUN3ME2xN{4{OjJzIN88US=>	NXfwPYc1W0GQR1XS
SW684	M4qyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTF\|Lkm3PVch\|ryP	NHP6OIhUSU6JRWK=
NCI-H1650	NEnPRmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\nOmlEPTB;MUWuNFQ1PyEQvF2=	Ml\qV2FPT0WU
EW-13	NEL6OYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYKxNmNnUUN3ME2xOU4zODJzIN88US=>	M3u1RnNCVkeHUh?=
EC-GI-10	MnvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\UTWM2OD1zNT64OlQ1KM7:TR?=	NX3XUHFDW0GQR1XS
CHP-126	NH\3TZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3P4XmlEPTB;MUeuNVkyQCEQvF2=	NHLFNZVUSU6JRWK=
NCI-H226	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTF6LkC0NFMh\|ryP	MkT6V2FPT0WU
NCI-H1838	NHrKZlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTJyLkG4OFgh\|ryP	NUPzVG9PW0GQR1XS
EW-11	NVXwfFRiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYL2OJUyUUN3ME2yOE4zPzF6IN88US=>	Mni5V2FPT0WU
EB2	M3LS[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWrPT5lJUUN3ME2zNU42OzF6IN88US=>	M4XlO3NCVkeHUh?=
D-502MG	M1K5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmfnTWM2OD12Mz65NlI6KM7:TR?=	M4HjfXNCVkeHUh?=
U-698-M	NXHRVXhPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGD0SIJKSzVyPUS4Mlg3PzFizszN	MoPmV2FPT0WU
ES3	NGPV[4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fhW2lEPTB;NEmuN\|g6OyEQvF2=	MX7TRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	ATF4 / p-S6K(T389) / S6K / p-eIF2α(S51) / eIF2α / 4EBP1 / eIF3b; PubMed: 28494858 Cell Rep 4E-BPs are required for mTOR control of ATF4. 4E-BP1/2 wild-type (WT), double knockout (DKO), or DKO MEFs stably expressing 4ebp1 (DKO + 4ebp1) were treated with vehicle (DMSO) or 250 nM Torin 1 for 4 hr. Cell extracts were analyzed by immunoblotting for the indicated proteins. LC3 / p62 / PARP / pAKT(S473) / p4EBP1(S65) / pS6K1(T389) / pS6(S235/236); PubMed: 24126619 Int J Oncol Cells were treated with increasing doses of the mTOR inhibitors, torin 1 (A) and rapamycin (B), in RPMI-1640 containing 10% FBS for 2 days. LC3 processing, p62 accumulation, PARP cleavage, AKT phosphorylation and mTOR pathway activity (indicated by phosphorylation of 4E-BP, S6K1 and S6) were analyzed by western blotting of total cell lysates. GAPDH was the control for protein loading. p-mTOR(S2481) / mTOR / rictor / Sin1 / p-Akt S473 / p-Akt T450 / p-Akt T308 / p-S6K1 T389 / S6K1; PubMed: 21965657 J Biol Chem mTOR kinase activity controls abundance of SIN1. MDA-MB-435 cells were incubated with specific mTOR inhibitor (0.5 μm TORIN) for 24 or 48 h and analyzed. Vinculin / p-S6; PubMed: 28757207 Mol Cell A375 cells were treated with Torin1 for 48 h and localization of proteins was visualized by confocal microscopy. Scale bar, 50 μm. Focal adhesion size was measured by Fiji program.	28494858 24126619 21965657 28757207
Immunofluorescence	lipin-1; PubMed: 28347999 FASEB J Inhibition of mTOR activity promoted the nuclear translocation of lipin-1. After treatment with or without torin 1 for 4 h, cells expressing HA-lipin-1 were fixed and stained with a rabbit HA antibody followed by Alexa 594–conjugated goat anti-rabbit secondary antibody. Nuclei were stained with DAPI. Scale bars, 20 μM.	28347999
Growth inhibition assay	Cell viability; PubMed: 28757207 Mol Cell Cancer cell lines were grown in complete media with/without mTOR inhibitor, Torin1 (250 nM). Media and Torin1 were replaced every 2 days and cells were counted at the indicated time points. Data are the means ± SD of three separate experiments performed in triplicate.	28757207

In vivo

Torin1 is efficacious at a dose of 20 mg/kg in a U87MG xenograft model and demonstrates good pharmacodynamic inhibition of downstream effectors of mTOR in tumor and peripheral tissues. ^[2]

Protocol

Kinase Assay:^[1]	+ Expand mTORC1 and mTORC2 in Vitro Kinase Assays: To produce soluble mTORC1, HEK-293T cell lines that stably express N-terminally FLAG-tagged Raptor are generated using vesicular stomatitis virus G-pseudotyped MSCV retrovirus. For mTORC2, similar HeLa cells that stably express N-terminally FLAG-tagged Protor-1 are generated. Both complexes are purified by lysing cells in 50 mm HEPES, pH 7.4, 10 mm sodium pyrophosphate, 10 mm sodium β-glycerophosphate, 100 mm NaCl, 2 mm EDTA, 0.3% CHAPS. Cells are lysed at 4 °C for 30 min, and the insoluble fraction is removed by microcentrifugation at 13,000 rpm for 10 min. Supernatants are incubated with FLAG-M2 monoclonal antibody-agarose for 1 h and then washed three times with lysis buffer and once with lysis buffer containing a final concentration of 0.5 M NaCl. Purified mTORC1 is eluted with 100 μg/mL 3×FLAG peptide in 50 mm HEPES, pH 7.4, 100 mm NaCl. Eluate can be aliquoted and stored at -80 °C. Substrates S6K1 and Akt1 are purified. Kinase assays are performed for 20 min at 30 °C in a final volume of 20 μL consisting of the kinase buffer (25 mm HEPES, pH 7.4, 50 mm KCl, 10 mm MgCl₂, 500 μm ATP) and 150 ng of inactive S6K1 or Akt1 as substrates. Reactions are stopped by the addition of 80 μL of sample buffer and boiled for 5 min. Samples are subsequently analyzed by SDS-PAGE and immunoblotting.
Cell Research:^[1]	+ Expand Cell lines: MEFs Concentrations: ~250 nM Incubation Time: 4 days Method: Cell viability is assessed with the CellTiter-Glo Luminescent Cell Viability Assay. On Day 0, 96-well plates are seeded with 500 cells per well and grown overnight. On Day 1, cells are treated with the appropriate compounds and subsequently analyzed on Days 3-5. For analysis, plates are incubated for 60 min at room temperature; 50 μL of CellTiter-Glo reagent is added to each well, and plates are mixed on an orbital shaker for 12 min. Luminescence is quantified on a standard plate luminometer. (Only for Reference)
Animal Research:^[2]	+ Expand Animal Models: U87MG xenograft model Formulation: Torin1 powder is first dissolved at 25 mg/mL in 100% N-methyl-2-pyrrolidone and subsequently diluted 1:4 with sterile 50% PEG400 to a final concentration of 5 mg/mL Dosages: 20 mg/kg Administration: Administered via i.p. once daily (Only for Reference)

References

[4] Dowling RJ, et al, Science, 2010, 328(5982), 1172-1176.

+ Expand

Solubility (25°C)

In vitro	DMSO	2 mg/mL (3.29 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 20% NMP+50% PEG 400 For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Torin 1 SDF

Molecular Weight	607.62
Formula	C₃₅H₂₈F₃N₅O₂
CAS No.	1222998-36-8
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to re-constitute the inhibitor for i.p. administration?
Answer:
S2827 Torin 1 can be dissolved in 5% DMSO/30% PEG 300/ddH2O at 0.25 mg/ml clearly, and in 10% DMSO/corn oil at 0.5 mg/ml, it is also a clear solution.

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Selective mTOR inhibitor

Rapamycin (Sirolimus) : mTORC1-selective, IC50=~0.1 nM.
Most Potent mTOR Inhibitor

Rapamycin (Sirolimus) : mTOR, IC50=~0.1 nM.
FDA-approved mTOR Inhibitor

Temsirolimus (CCI-779, NSC 683864) : Approved by FDA for Renal Cell Carcinoma (RCC).
Newest mTOR Inhibitor

XL388 ^New : Highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.

Related mTOR Products4

MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.
Dorsomorphin (Compound C) ^New

Dorsomorphin is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Everolimus (RAD001)

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.
AZD8055

AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

Features:First drug to inhibit both types of mTOR protein.
Temsirolimus (CCI-779, NSC 683864)

Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay.
Sapanisertib (INK 128, MLN0128,TAK-228)

Sapanisertib (INK 128, MLN0128) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.
Tacrolimus (FK506)

Tacrolimus (FK506) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex.
KU-0063794

KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

Choose Your Country or Region

By Signaling Pathways

By product type

Torin 1

Cited by 16 Publications

5 Customer Reviews

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Torin 1 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products4

Choose Your Country or Region

By Signaling Pathways

By product type

Torin 1

Cited by 16 Publications

5 Customer Reviews

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Torin 1 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)